ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
12.62
+0.13 (1.00%)
Mar 31, 2025, 1:44 PM EDT - Market open

ARS Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
89.150.031.325.5117.84
Revenue Growth (YoY)
297063.33%-97.72%-76.10%-69.13%-
Cost of Revenue
20.5620.2717.1220.2714.07
Gross Profit
68.59-20.24-15.8-14.773.77
Selling, General & Admin
71.6847.2818.664.694.23
Operating Expenses
71.6847.2818.664.694.23
Operating Income
-3.08-67.52-34.46-19.45-0.47
Interest Expense
----0.8-0.4
Currency Exchange Gain (Loss)
-----0.2
Other Non Operating Income (Expenses)
4.126.011.120.010
EBT Excluding Unusual Items
1.03-61.51-33.34-20.24-1.07
Gain (Loss) on Sale of Investments
7.256.85-0.29--
Gain (Loss) on Sale of Assets
-0.3---
Pretax Income
8.29-54.37-34.68-20.24-1.07
Income Tax Expense
0.29----
Net Income
8-54.37-34.68-20.24-1.07
Net Income to Common
8-54.37-34.68-20.24-1.07
Shares Outstanding (Basic)
9795402920
Shares Outstanding (Diluted)
10295402920
Shares Change (YoY)
7.54%138.30%38.39%42.81%-
EPS (Basic)
0.08-0.57-0.87-0.70-0.05
EPS (Diluted)
0.08-0.57-0.87-0.70-0.05
Free Cash Flow
12.99-59.44-40.28-17.629.07
Free Cash Flow Per Share
0.13-0.62-1.01-0.610.45
Gross Margin
76.94%---268.20%21.11%
Operating Margin
-3.46%-225066.67%-2618.54%-353.32%-2.63%
Profit Margin
8.97%-181216.67%-2635.41%-367.65%-5.97%
Free Cash Flow Margin
14.57%-198136.67%-3060.56%-319.94%50.86%
EBITDA
-3-67.45-34.43-19.24-0.46
EBITDA Margin
-3.37%----2.60%
D&A For EBITDA
0.080.070.030.210.01
EBIT
-3.08-67.52-34.46-19.45-0.47
EBIT Margin
-3.46%----2.63%
Effective Tax Rate
3.48%----
Revenue as Reported
89.150.03--17.84
Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q